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The age-incidence curve for testicular cancer has a distinctive The reason that many epidemiologists have used aggregate
shape: it rises to a peak at around age 30, declines to a low data is, of course, because of the lack of routinely published
level by age 50, and finally increases again in old age. This data by histology. Thus, although the cancer registries of
pattern is also evident in mortality statistics and the rise at England and Wales code testicular tumours according to site
older ages is much more marked (Figure 1). Germ cell (i.e. testis) and histology (World Health Organisation, 1976),
tumours predominate at younger ages, but it is well known the routinely published cancer incidence statistics for
to pathologists and clinicians who treat testicular cancer that England and Wales (see, e.g., OPCS, 1985a) tabulate
the majority of cases occurring at older ages are lymphomas numbers of registrations by site alone. Death certificates are
and other non-germ cell tumours arising in the testis (see only coded by site (World Health Organisation, 1978), but
Peckham, 1981). This fact has been noted in the lymphomas are allocated a separate code (or codes), so that
epidemiological literature (see e.g., Schottenfeld et al., 1980), contrary to the situation with incidence data, a death from a
but the aggregate data (all histologies) covering an age range lymphoma arising in the testis is not meant to be coded to
extending into the older age groups are nevertheless testis. Cancer mortality statistics (see e.g., OPCS, 1985b) are
frequently used for epidemiological research purposes thus only published by site. Such published data (Office of
without specific attention being drawn to the problem that Population Censuses and Surveys, 1970-74; 1979-85; 1984;
such data reflect a mixture of tumour types (see e.g., Cancer Registrar General, 1975) were used to calculate the rates
Research Campaign, 1981; Davies, 1981; Gardner et al., shown in Figure 1.
1983; McDowall & Balarajan, 1986; and most recently The wide disparity between the mortality and incidence
Osterlind, 1986). It is likely that there are different causes of data even in 1968-72 (Figure 1) before the use of
at least the major different types of tumour arising in the sophisticated staging techniques and combination chemo-
testis; the use of combined data on tumours with such therapy shows that mortality data are unlikely to be useful
different histologies can do nothing but hinder our search for epidemiological research purposes. We have, therefore, in
for clues to their causes, and in particular to the causes of this paper concentrated on incidence data.
the continuing substantial increase in incidence of seminomas As we noted above, cancer registries do code testicular
and teratomas of the testis. tumours by histology (World Health Organisation, 1976),
The purposes of this note are: (1) to draw the attention of and these incidence data, together with appropriate popula-
epidemiologists to the fact that epidemiological aspects of tions, were kindly supplied to us by the Thames Cancer
germ cell tumours can nevertheless be very satisfactorily Registry for the South Thames Region for the 15-year period
studied using aggregate incidence data if attention is 1968-82. One thousand seven hundred and seventy new cases
restricted to the age range 15 to 50; (2) to draw the attention of testicular cancer in residents of the South Thames Region
of the Office of Population Censuses and Surveys (OPCS) were registered during this period. Figure 2a shows the
and the regional cancer registries to the need to publish all incidence rates by age for all testicular tumours with the
future incidence data by histology (at least broken down into characteristic peak around age 30 and a secondary increase
germ cell' tumours and 'other'); and (3) to draw the after age 65. In Figure 2b the incidence rates shown in
attention of OPCS to the strong possibility that many Figure 2a are shown divided into seminoma (pure
lymphomas of the testis are being wrongly coded to testis seminoma), teratoma (with or without seminomatous
(rather than Iymphoma) in current mortality statistics. elements) and 'other'. It is clear from this figure that the
secondary increase in incidence after age 65 occurs almost
entirely in the 'other' category of tumours. Seminomas and
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until age 70-74 with possibly a very minor rise at age 75±.
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Figure 1 Testicular cancer incidence and mortality rates, antibodies used comprised PD7/26 (Dako), Cam 5.2 (ICRF),
England and Wales: 1968s-72. 8B6 (ICRF), anti-desmin (Dako) and anti-vimetin (Dako).
PD7/26, CAM 5.2 and 8B6 distinguish between lymphoma,
teratoma (with and without seminoma) and pure seminoma
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Figure 2 (a) Testicular cancer incidence rates, South Thames
Region: 1968-82; (b) Testicular cancer incidence rates (by
histology), South Thames Region: 1968-82.
with and without muscle differentiation (Gabbiani et al.,
1981).
Six blocks were received from cases under age 70, all
registered as 'carcinoma'. Four of these cases had been
reported by the hospital pathologist as teratomas: the
diagnoses being wrongly recorded by the Registry. One of
the other two cases had been diagnosed as an anaplastic
carcinoma; no hospital pathology report was available for
the sixth case. On review we diagnosed 5 germ-cell tumours:
I seminoma (hospital pathologist diagnosis: teratoma), 3
teratomas (hospital pathologist diagnoses: 2 teratomas, 1
anaplastic carcinoma) and 1 yolk sac tumour (hospital
pathologist diagnosis: teratoma), so our histological findings
were not consistent with the original reports in 3 cases. The
sixth block showed a benign adrenal tumour consistent with
an origin in ectopic adrenal tissue present in the testis.
There were 18 blocks from patients aged 70 and over; the
histological diagnosis recorded by the Registry agreed with
the diagnosis made by the hospital pathologist in 17 of the
18 cases (I hospital pathologist's diagnosis of teratoma was
recorded as a seminoma). On review, one of the two hospital
pathologists' diagnoses of seminoma was identified as a
lymphoma, as was one of the two diagnoses of teratoma,
and one of the II diagnoses of lymphoma was identified as a
seminoma. Our review agreed with the hospital pathologists
other 2 diagnoses of germ cell tumours (1 teratoma, yolk
sac tumour).
The data for England and Wales shown in Figure 1 show
that there is a minor peak in the youngest age groups, 0-4
and 5-9 years. A large proportion of testicular tumours in
these age groups are well known to be of two very specific
types, paratesticular embryonal sarcomas and yolk sac
tumours (Peckham, 1981): although the latter are germ cell
tumours, they are distinct from seminomas and the usual
teratomas.
Inspection of Figure 2b shows that between the ages of 15
and 50 the overwhelming majority of testicular cancer cases
are either seminomas or teratomas, and our pathology
review of 'other' tumours in this age range, although
admittedly of only a very small number, suggests that a clear
majority of these 'other' tumours are also likely to be either
seminomas or teratomas. In the absence of data by
particular histology, use of aggregate incidence data for the
age group 15-49 years can therefore be safely used to
investigate the most important issue of the continuing rise in
seminomas and teratomas. This procedure is much to be
preferred to the current common practice of using data
covering all age groups.
We have investigated the change in incidence of germ cell
testicular cancer in England and Wales over the three 5 year
periods 1968-72, 1973-77 and 1978-82 using this scheme.
There was a steady rise in incidence at all ages between 15
and 50; for 1978-82 the cumulative incidence between ages
15 and 50 was 206.1 per 100,000, i.e. 1 in 485 men would be
affected between ages 15 and 50, compared to 1 in 625 men
in 1968-72 (a 29% rise). [This 29% increase in incidence of
testicular cancer between 1968-72 and 1978-82 is likely to be
an underestimate, in part due to late registration of cases
after the national data are published (Swerdlow, 1986).]
The above analysis shows that national incidence statistics
need to be improved by subdividing testicular cancer
reporting into at least two categories (germ cell tumours and
'other'). Subdivision of germ cell tumours into seminomas
and teratomas is considered by certain investigators to be
epidemiologically interesting: it is clear, for example, that
their age distributions are different (Figure 2b). However,
the 'teratoma' classification includes tumours with
seminomatous elements, and we saw above in our limited
pathology review that at younger ages our diagnosis
disagcreed with that of the hospital pathologist in 3 out of 5
cclses, anIId ait older ages 2 out of 4 hospital pathologists'
diagnoses of germ cell tumours were found to be
lymphomas. In these circumstances it is not clear how useful
a tumour classification based on reports by multiple hospital
pathologists would be. We have, moreover, not found any
interesting differences between seminomas and teratomas in
our epidemiological studies (Depue et al., 1983; Pike et al.,
1986).
Figure I shows that there is a marked rise in the mortality
rate at older ages and the analysis shown in Figure 2b makes
it evident that this rise must be due to 'other' tumours
(almost all of which are lymphomas). It is therefore almost
certain that a substantial number of deaths from testicular
lymphomas are being coded incorrectly to testis: this issue
needs to be investigated by the Offtice of Population
Censuses and Surveys.
We thank Helen Jones (Thames Cancer Registry) for supplying
incidence data, all the pathologists who kindly supplied blocks and
slides, Prof Alan Horwich for helpful comments on an earlier draft
of the paper, Eileen Williams and Cynthia Taylor for data
processing, and Sybil Farrell and Sarah Jones who prepared the
manuscript.
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